GRI Bio Statistics
Total Valuation
GRI Bio has a market cap or net worth of $1.14 million. The enterprise value is -$2.80 million.
| Market Cap | 1.14M |
| Enterprise Value | -2.80M |
Important Dates
The last earnings date was Friday, May 10, 2024, before market open.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
GRI Bio has 3.77 million shares outstanding. The number of shares has increased by 2,786.57% in one year.
| Shares Outstanding | 3.77M |
| Shares Change (YoY) | +2,786.57% |
| Shares Change (QoQ) | +794.23% |
| Owned by Insiders (%) | 17.75% |
| Owned by Institutions (%) | 4.60% |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 0.02.
| PE Ratio | 0.02 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.64, with a Debt / Equity ratio of 0.05.
| Current Ratio | 2.64 |
| Quick Ratio | n/a |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.96 |
Financial Efficiency
Return on equity (ROE) is -548.10% and return on invested capital (ROIC) is -416.75%.
| Return on Equity (ROE) | -548.10% |
| Return on Assets (ROA) | -290.50% |
| Return on Capital (ROIC) | -416.75% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.19M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.27% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -99.27% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 4.45 |
| Relative Strength Index (RSI) | 28.41 |
| Average Volume (30 Days) | 284,541 |
Short Selling Information
The latest short interest is 24,331, so 0.64% of the outstanding shares have been sold short.
| Short Interest | 24,331 |
| Short Previous Month | 16,248 |
| Short % of Shares Out | 0.64% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -12.29M |
| Pretax Income | -12.77M |
| Net Income | -12.77M |
| EBITDA | -11.85M |
| EBIT | -11.86M |
| Earnings Per Share (EPS) | $16.07 |
Balance Sheet
The company has $4.09 million in cash and $152,000 in debt, giving a net cash position of $3.94 million or $1.04 per share.
| Cash & Cash Equivalents | 4.09M |
| Total Debt | 152,000 |
| Net Cash | 3.94M |
| Net Cash Per Share | $1.04 |
| Equity / Book Value | 2.80M |
| Book Value Per Share | 0.74 |
| Working Capital | 2.75M |
Cash Flow
In the last 12 months, operating cash flow was -$9.08 million and capital expenditures -$8,000, giving a free cash flow of -$9.09 million.
| Operating Cash Flow | -9.08M |
| Capital Expenditures | -8,000 |
| Free Cash Flow | -9.09M |
| FCF Per Share | -$2.20 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GRI Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,786.57% |
| Shareholder Yield | -2,786.57% |
| Earnings Yield | -1,120.63% |
| FCF Yield | -797.00% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 30, 2024. It was a reverse split with a ratio of 1:7.
| Last Split Date | Jan 30, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |